Song Pan, Yan Xiaoqing, Jiang Yanhui, Ye Yuchu, Wang Jingyi, Han Ping
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2022 Apr;36(4):315-320. doi: 10.13201/j.issn.2096-7993.2022.04.017.
Over the past few years, the FDA has approved PD-1/L1 inhibitor for the treatment of advanced head and neck squamous cell carcinoma, involving PD-1/L1 inhibitor monotherapy, PD-1/L1 inhibitor combined with chemoradiotherapy, combined with targeted therapy, combined with neoadjuvant immunotherapy and duplex-block of immune checkpoints and so on. Herein, we briefly review the latest research results in this field, and summarize the application and efficacy of immunotherapy in the treatment of head and neck squamous cell carcinoma， which will benefits such patients to develop more precise and individualized treatment plans.
在过去几年中，美国食品药品监督管理局（FDA）已批准PD-1/L1抑制剂用于治疗晚期头颈部鳞状细胞癌，包括PD-1/L1抑制剂单药治疗、PD-1/L1抑制剂联合放化疗、联合靶向治疗、联合新辅助免疫治疗以及免疫检查点双重阻断等。在此，我们简要回顾该领域的最新研究成果，并总结免疫疗法在头颈部鳞状细胞癌治疗中的应用及疗效，这将有助于此类患者制定更精准、个性化的治疗方案。
